Lion Point Capital, LP
An institutional investment manager in NEW YORK, NY. Its Form 13F for the quarter ended Jun 30, 2026, filed Aug 14, 2026. SEC CIK 1643354.
- Reported value$20.9m
- Positions35
Holdings: 35 positions
The filing on sec.govAs filed, largest first. Reported value is what the manager stated for each position at the quarter end, in US dollars; it is filing data, not a price. Weight is the position's share of the total reported value. Changes compare with the 13F for the quarter ended 2026-03-31.
| Issuer | Class | CUSIP | Reported value$k | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| CUE Biopharma IncCUE | COM | 22978P205 | 1,670 | 8.0% | 52,928 | New+52,928 | |
| Praxis Precision Medicines IPRAX | COM NEW | 74006W207 | 1,490 | 7.1% | 4,450 | Unchanged | |
| Moonlake ImmunotherapeuticsMLTX | CLASS A ORD | 61559X104 | 1,314 | 6.3% | 67,500 | Unchanged | |
| Fennec Pharmaceuticals IncFENC | COM | 31447P100 | 1,209 | 5.8% | 112,434 | Unchanged | |
| Royalty Pharma plc | SHS CLASS A | G7709Q104 | 1,200 | 5.7% | 21,400 | Unchanged | |
| Compass Pathways plcCMPS | SPONSORED ADS | 20451W101 | 1,132 | 5.4% | 80,000 | Unchanged | |
| Milestone Pharmaceuticals inMIST | COM | 59935V107 | 1,099 | 5.3% | 820,000 | Unchanged | |
| Benitec Biopharma IncBNTC | COM NEW | 08205P209 | 830 | 4.0% | 62,000 | Unchanged | |
| Syndax Pharmaceuticals IncSNDX | COM | 87164F105 | 787 | 3.8% | 36,000 | Unchanged | |
| Biohaven Ltd | COM | G1110E107 | 769 | 3.7% | 51,700 | Unchanged | |
| Geron CorpGERN | COM | 374163103 | 740 | 3.5% | 578,000 | Unchanged | |
| Uniqure NV | SHS | N90064101 | 677 | 3.2% | 14,700 | Unchanged | |
| Ardelyx IncARDX | COM | 039697107 | 656 | 3.1% | 128,650 | Unchanged | |
| Lantheus Holdings IncLNTH | COM | 516544103 | 610 | 2.9% | 5,500 | Unchanged | |
| Disc Medicine IncIRON | COM | 254604101 | 592 | 2.8% | 8,100 | Unchanged | |
| Sarepta Therapeutics IncSRPT | COM | 803607100 | 512 | 2.4% | 28,500 | Unchanged | |
| Humacyte IncHUMA | COM | 44486Q103 | 507 | 2.4% | 650,000 | Unchanged | |
| Kura Oncology IncKURA | COM | 50127T109 | 505 | 2.4% | 46,000 | Unchanged | |
| Viatris IncVTRS | COM | 92556V106 | 440 | 2.1% | 27,700 | Unchanged | |
| Dyne Therapeutics IncDYN | COM | 26818M108 | 400 | 1.9% | 18,000 | Unchanged | |
| Bridgebio Pharma IncBBIO | COM | 10806X102 | 372 | 1.8% | 5,000 | Unchanged | |
| Edgewise Therapeutics IncEWTX | COM | 28036F105 | 370 | 1.8% | 9,100 | Unchanged | |
| Pacira Biosciences IncPCRX | COM | 695127100 | 342 | 1.6% | 13,500 | Unchanged | |
| Regenxbio IncRGNX | COM | 75901B107 | 319 | 1.5% | 26,600 | Unchanged | |
| Rocket Pharmaceuticals IncRCKT | COM | 77313F106 | 294 | 1.4% | 86,000 | Unchanged | |
| Janux Therapeutics IncJANX | COM | 47103J105 | 292 | 1.4% | 19,000 | Unchanged | |
| Mineralys Therapeutics IncMLYS | COM | 603170101 | 283 | 1.4% | 10,500 | Unchanged | |
| GH Research plc | ORDINARY SHARES | G3855L106 | 274 | 1.3% | 10,200 | Unchanged | |
| Seres Therapeutics IncMCRB | COM NEW | 81750R201 | 249 | 1.2% | 31,570 | Unchanged | |
| Azenta IncAZTA | COM | 114340102 | 248 | 1.2% | 9,700 | Unchanged | |
| Jasper Therapeutics IncJSPR | COM NEW | 471871202 | 196 | 0.9% | 465,000 | Unchanged | |
| Innoviva IncINVA | COM | 45781M101 | 186 | 0.9% | 8,200 | Unchanged | |
| Innate Pharma S aIPHA | SPONSORED ADS | 45781K204 | 149 | 0.7% | 81,151 | Unchanged | |
| Arcutis Biotherapeutics IncARQT | COM | 03969K108 | 138 | 0.7% | 5,250 | Unchanged | |
| Spruce Biosciences IncSPRB | COM NEW | 85209E208 | 54.0 | 0.3% | 1,000 | Unchanged |
Sold out: 1 position
Held at the end of the quarter before and not reported this quarter.
| Issuer | Class | CUSIP | Reported value$ | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| CUE Biopharma Inc | COM | 22978P106 | 0.0 | 0.0% | 0 | Sold out−2,202,854 |
Source: SEC EDGAR, Form 13F-HR, accession 0001013594-26-000908 (on sec.gov). Last ingested by Listed: Oct 22, 2026, 05:26 ET. Listed shows no prices and gives no investment advice.